This conference brings together the academic, regulatory, pharmaceutical communities to discuss therapeutic endpoints, trial designs, appropriate patient populations and safety concerns with regards to novel therapeutic approaches for the treatment of chronic hepatitis B and D.
8.75 AMA PRA Category 1 Credits™ - maximum
8.75 ABIM MOC points
Venue: Washington Marriott at Metro Center
June 3-4, 2022
Washington, D.C. 20005, United States